KRAS and metastatic neoplasm: KRAS mutation detection in LB for metastatic disease was associated with worse OS (median 14.5 vs. 31.3 months, HR = 2.7, 95%CI = 1.7–4.3, P < 0.001; Fig. 2-E) but the OS difference was not significant in localized disease (Figure S1-A).